Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest update is out from PYC Therapeutics Limited ( (AU:PYC) ).
PYC Therapeutics Limited has announced a plan to raise up to approximately $146 million through an accelerated non-renounceable entitlement offer. The funds will be used to support the progression of its drug pipeline through critical human trials, with all four programs expected to be funded through FY27. This move, backed by key shareholder support and underwriting agreements, is expected to strengthen PYC’s position in the biotechnology sector by enabling the advancement of its innovative treatments for blinding eye diseases.
More about PYC Therapeutics Limited
PYC Therapeutics Limited operates in the biotechnology industry, focusing on developing first-in-class drug candidates to address major unmet medical needs. The company is committed to advancing its pipeline of innovative treatments, particularly in the area of blinding eye diseases.
YTD Price Performance: -2.65%
Average Trading Volume: 405,310
Technical Sentiment Consensus Rating: Hold
Current Market Cap: A$599.6M
For an in-depth examination of PYC stock, go to TipRanks’ Stock Analysis page.
